Principal Securities Inc. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 18.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,020 shares of the company's stock after selling 7,767 shares during the quarter. Principal Securities Inc.'s holdings in Novo Nordisk A/S were worth $2,926,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in NVO. Creative Planning grew its holdings in Novo Nordisk A/S by 4.7% in the third quarter. Creative Planning now owns 294,799 shares of the company's stock worth $35,102,000 after purchasing an additional 13,203 shares during the last quarter. Resonant Capital Advisors LLC lifted its position in Novo Nordisk A/S by 3.1% during the third quarter. Resonant Capital Advisors LLC now owns 7,047 shares of the company's stock valued at $839,000 after purchasing an additional 212 shares during the period. New Century Financial Group LLC grew its holdings in Novo Nordisk A/S by 12.9% during the third quarter. New Century Financial Group LLC now owns 1,954 shares of the company's stock worth $233,000 after acquiring an additional 224 shares during the period. Cyndeo Wealth Partners LLC lifted its stake in shares of Novo Nordisk A/S by 12.8% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 3,671 shares of the company's stock valued at $437,000 after purchasing an additional 418 shares during the period. Finally, OLD National Bancorp IN raised its position in shares of Novo Nordisk A/S by 30.5% in the third quarter. OLD National Bancorp IN now owns 4,399 shares of the company's stock worth $524,000 after acquiring an additional 1,027 shares during the period. Institutional investors own 11.54% of the company's stock.
A number of equities research analysts recently issued reports on the stock. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $145.25.
Read Our Latest Stock Report on Novo Nordisk A/S
Novo Nordisk A/S stock opened at $77.94 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74. The firm has a 50 day moving average price of $88.65 and a 200 day moving average price of $109.54. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15. The company has a market capitalization of $349.75 billion, a PE ratio of 23.69, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts expect that Novo Nordisk A/S will post 3.86 earnings per share for the current year.
The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 21.88%.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.